US Stock MarketDetailed Quotes
IGC IGC Pharma
- 0.4174
- -0.0136-3.16%
Close Jun 14 16:00 ET
- 0.4085
- -0.0089-2.13%
Post 19:57 ET
31.46MMarket Cap-1605P/E (TTM)
0.4278High0.3951Low185.22KVolume0.4233Open0.4310Pre Close75.76KTurnover0.27%Turnover RatioLossP/E (Static)75.37MShares0.909952wk High3.48P/B28.53MFloat Cap0.250152wk Low--Dividend TTM68.35MShs Float71.1000Historical High--Div YieldTTM7.59%Amplitude0.0001Historical Low0.4090Avg Price1Lot Size
About IGC Pharma Company
IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.
Company Profile
SymbolIGC
Company NameIGC Pharma
Listing DateApr 13, 2006
Founded2005
CEOMr. Ram Mukunda
MarketAMEX
Employees61
Securities TypeOrdinary Shares
Fiscal Year Ends03-31
Address10224 Falls Road
CityPotomac
ProvinceMaryland
CountryUnited States of America
Zip Code20854
Phone1-301-983-0998
Websitehttp://www.igcinc.us
Company Executives
- Name
- Position
- Salary
- Ram Mukunda
- President, Chief Executive Officer and Director
- 1.01M
- Claudia Grimaldi
- Director, Vice President, Principal Financial Officer and Chief Compliance Officer
- 320.00K
- Rohit Goel
- Principal Accounting Officer
- --
- Richard Prins
- Chairman of the Board
- 75.00K
- Terry L. Lierman
- Independent Director
- --
- James P Moran
- Independent Director
- 43.00K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg